

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7294410

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SAMUEL C. WAGNER	04/23/2015
THOMAS E. ICHIM	04/15/2015
JULIA S. SZYMANSKI	06/03/2016
SANTOSH KESARI	04/15/2015
AMIT PATEL	04/22/2015
BORIS MINEV	04/14/2015
RECEIVING PARTY DATA	
Name:	BATU BIOLOGICS, INC.
Street Address:	9255 TOWNE CENTRE DRIVE, SUITE 450
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17715558
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6504939300
Email:	patentdocket@wsgr.com, bmaclean@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, MASSACHUSETTS 94304
ATTORNEY DOCKET NUMBER:	56371-720.306
NAME OF SUBMITTER:	SANJUKTA GHOSH
SIGNATURE:	/Sanjukta Ghosh/
DATE SIGNED:	04/22/2022
Total Attachments: 6	

source=56371720306inventorsassignment#page1.tif
source=56371720306inventorsassignment#page2.tif
source=56371720306inventorsassignment#page3.tif
source=56371720306inventorsassignment#page4.tif
source=56371720306inventorsassignment#page5.tif
source=56371720306inventorsassignment#page6.tif

ASSIGNMENT OF RIGHTS: PATENT APPLICATION


Samuel C. Wagner ("Assignor") is an owner of "Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer", as described in the U.S. Patent Application received by the United States Patent and Trademark office on February 19, 2015, U.S. Patent and Trademark office Serial Number: 62/118027, (the "Patent Application"). Batu Biologics, Inc. ("Assignee") desires to acquire all rights in and to the Patent Application and the patent (and any reissues or extensions) that may be granted.

Therefore, for valuable consideration, the receipt of which is acknowledged, Assignor assigns to Assignee 100% of his right, title, and interest in the invention and Patent Application (as well as such rights in any divisions, continuations in whole or part or substitute applications) to Assignee for the entire term of the issued Patent and any reissues or extensions that may be granted and for the entire terms of any and all foreign patents that may issue from foreign applications (as well as divisions, continuations in whole or part or substitute applications) filed claiming the benefit of the Patent Application.

Assignor authorizes the United States Patent and Trademark Office to issue any Patents resulting from the Patent Application to Assignee according to the percentage interest indicated in this assignment. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this assignment not been made.

Assignor further agrees to: (a) cooperate with Assignee in the prosecution of the Application and foreign counterparts; (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer; and (c) perform such other acts as Assignee lawfully may request to obtain or maintain the Patent for the invention in any and all countries.

Date: April 23rd, 2015


Samuel C. Wagner
Assignor

ASSIGNMENT OF RIGHTS: PATENT APPLICATION


Dr. Thomas E. Ichim ("Assignor") is an owner of "Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer", as described in the U.S. Patent Application received by the United States Patent and Trademark office on February 19, 2015, U.S. Patent and Trademark office Serial Number: 62/118027, (the "Patent Application"). Batu Biologies, Inc. ("Assignee") desires to acquire all rights in and to the Patent Application and the patent (and any reissues or extensions) that may be granted.

Therefore, for valuable consideration, the receipt of which is acknowledged, Assignor assigns to Assignee 100% of his right, title, and interest in the invention and Patent Application (as well as such rights in any divisions, continuations in whole or part or substitute applications) to Assignee for the entire term of the issued Patent and any reissues or extensions that may be granted and for the entire terms of any and all foreign patents that may issue from foreign applications (as well as divisions, continuations in whole or part or substitute applications) filed claiming the benefit of the Patent Application.

Assignor authorizes the United States Patent and Trademark Office to issue any Patents resulting from the Patent Application to Assignee according to the percentage interest indicated in this assignment. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this assignment not been made.

Assignor further agrees to: (a) cooperate with Assignee in the prosecution of the Application and foreign counterparts; (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer; and (c) perform such other acts as Assignee lawfully may request to obtain or maintain the Patent for the invention in any and all countries.

Date: Feb 19, 2015, 2015



Dr. Thomas E. Ichim
Assignor

ASSIGNMENT OF RIGHTS: PATENT APPLICATION

Julia S. Szymanski ("Assignor") is an owner of "Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer", as described in the U.S. Patent Application received by the United States Patent and Trademark office on February 19, 2015, U.S. Patent and Trademark office Serial Number: 62/118027, (the "Patent Application"). Batu Biologics, Inc. ("Assignee") desires to acquire all rights in and to the Patent Application and the patent (and any reissues or extensions) that may be granted.

Therefore, for valuable consideration, the receipt of which is acknowledged, Assignor assigns to Assignee 100% of her right, title, and interest in the invention and Patent Application (as well as such rights in any divisions, continuations in whole or part or substitute applications) to Assignee for the entire term of the issued Patent and any reissues or extensions that may be granted and for the entire terms of any and all foreign patents that may issue from foreign applications (as well as divisions, continuations in whole or part or substitute applications) filed claiming the benefit of the Patent Application.

Assignor authorizes the United States Patent and Trademark Office to issue any Patents resulting from the Patent Application to Assignee according to the percentage interest indicated in this assignment. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this assignment not been made.

Assignor further agrees to: (a) cooperate with Assignee in the prosecution of the Application and foreign counterparts; (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer; and (c) perform such other acts as Assignee lawfully may request to obtain or maintain the Patent for the invention in any and all countries.

Date: June 3, 2016

Julia Szymanski
Julia S. Szymanski
Assignor


ASSIGNMENT OF RIGHTS: PATENT APPLICATION

Dr. Santosh Kesari ("Assignor") is an owner of "Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer", as described in the U.S. Patent Application received by the United States Patent and Trademark office on February 19, 2015, U.S. Patent and Trademark office Serial Number: 62/118027, (the "Patent Application"). Batu Biologics, Inc. ("Assignee") desires to acquire all rights in and to the Patent Application and the patent (and any reissues or extensions) that may be granted.

Therefore, for valuable consideration, the receipt of which is acknowledged, Assignor assigns to Assignee 100% of his right, title, and interest in the invention and Patent Application (as well as such rights in any divisions, continuations in whole or part or substitute applications) to Assignee for the entire term of the issued Patent and any reissues or extensions that may be granted and for the entire terms of any and all foreign patents that may issue from foreign applications (as well as divisions, continuations in whole or part or substitute applications) filed claiming the benefit of the Patent Application.

Assignor authorizes the United States Patent and Trademark Office to issue any Patents resulting from the Patent Application to Assignee according to the percentage interest indicated in this assignment. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this assignment not been made.

Assignor further agrees to: (a) cooperate with Assignee in the prosecution of the Application and foreign counterparts; (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer; and (c) perform such other acts as Assignee lawfully may request to obtain or maintain the Patent for the invention in any and all countries.



Date: ___ April 15, _____, 2015

Dr. Santosh Kesari
Assignor

ASSIGNMENT OF RIGHTS: PATENT APPLICATION


Dr. Boris Minev ("Assignor") is an owner of "Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer", as described in the U.S. Patent Application received by the United States Patent and Trademark office on February 19, 2015, U.S. Patent and Trademark office Serial Number: 62/118027, (the "Patent Application"). Batu Biologies, Inc. ("Assignee") desires to acquire all rights in and to the Patent Application and the patent (and any reissues or extensions) that may be granted.

Therefore, for valuable consideration, the receipt of which is acknowledged, Assignor assigns to Assignee 100% of his right, title, and interest in the invention and Patent Application (as well as such rights in any divisions, continuations in whole or part or substitute applications) to Assignee for the entire term of the issued Patent and any reissues or extensions that may be granted and for the entire terms of any and all foreign patents that may issue from foreign applications (as well as divisions, continuations in whole or part or substitute applications) filed claiming the benefit of the Patent Application.

Assignor authorizes the United States Patent and Trademark Office to issue any Patents resulting from the Patent Application to Assignee according to the percentage interest indicated in this assignment. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this assignment not been made.

Assignor further agrees to: (a) cooperate with Assignee in the prosecution of the Application and foreign counterparts; (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer; and (c) perform such other acts as Assignee lawfully may request to obtain or maintain the Patent for the invention in any and all countries.

Date: 9/11/14, 2015


Dr. Boris Minev
Assignor